☆ 4.6 Meeting Abstract

The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC

JOURNAL OF THORACIC ONCOLOGY (2019)

Get Full Text
Add to Collection

Journal

JOURNAL OF THORACIC ONCOLOGY
Volume 14, Issue 10, Pages S625-S626

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2019.08.1318

Keywords

Chemotherapy; durvalumab; NSCLC

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.